inclusion criteria: 1. patients who are able to sign the informed consent form to partic-ipate in the clinical study; 2. patients of both sexes at the age of 18-65 years of age; 3. positive sars-cov-2 rna test result obtained by pcr during the current episode of covid-19 disease; 4. one or more clinical manifestations of ari (acute respiratory infection) or patient complaints: cough (dry or scanty sputum), edema (including during exercise), chest congestion, sore throat, nasal congestion, or mild rhinorrhea, impairment or loss of smell (hyposmia or anosmia), loss of taste (dysgeusia), conjunctivitis, weakness, muscle pain, headache, vomiting, diarrhea, skin manifestations). 5. patients with a moderate course of covid-19, determined on the basis of at least one of the criteria specified in the interim guide-lines of the ministry of health (assessed from the moment of mani-festation of the disease symptoms): * body т \> 38 °c * rr \> 22/min * spo2 \< 95 % (at the atmospheric air) * crp of the blood serum \> 10 mg/l 6. ct changes typical of viral lesions (minimal or moderate lesion vol-ume; ct 1-2, no more than 72 hours before screening) 7. patients meeting the requirements of the clinical study protocol; 8. negative pregnancy test (for women with preserved reproductive potential).

inclusion criteria: 1. patients who are able to sign the informed consent form to partic-ipate in the clinical study; 2. patients of both sexes at the age of 18-65 years of age; 3. positive sars-cov-2 rna test result obtained by pcr during the current episode of covid-19 disease; 4. one or more clinical manifestations of ari (acute respiratory infection) or patient complaints: cough (dry or scanty sputum), edema (including during exercise), chest congestion, sore throat, nasal congestion, or mild rhinorrhea, impairment or loss of smell (hyposmia or anosmia), loss of taste (dysgeusia), conjunctivitis, weakness, muscle pain, headache, vomiting, diarrhea, skin manifestations). 5. patients with a moderate course of covid-19, determined on the basis of at least one of the criteria specified in the interim guide-lines of the ministry of health (assessed from the moment of mani-festation of the disease symptoms): * body т \> 38 °c * rr \> 22/min * spo2 \< 95 % (at the atmospheric air) * crp of the blood serum \> 10 mg/l 6. ct changes typical of viral lesions (minimal or moderate lesion vol-ume; ct 1-2, no more than 72 hours before screening) 7. patients meeting the requirements of the clinical study protocol; 8. negative pregnancy test (for women with preserved reproductive potential).

inclusion criteria: patients who are able to sign the informed consent form to partic-ipate in the clinical study; patients of both sexes at the age of 18-65 years of age; positive sars-cov-2 rna test result obtained by pcr during the current episode of covid-19 disease; one or more clinical manifestations of ari (acute respiratory infection) or patient complaints: cough (dry or scanty sputum), edema (including during exercise), chest congestion, sore throat, nasal congestion, or mild rhinorrhea, impairment or loss of smell (hyposmia or anosmia), loss of taste (dysgeusia), conjunctivitis, weakness, muscle pain, headache, vomiting, diarrhea, skin manifestations). patients with a moderate course of covid-19, determined on the basis of at least one of the criteria specified in the interim guide-lines of the ministry of health (assessed from the moment of mani-festation of the disease symptoms): body т > 38 °c rr > 22/min spo2 < 95 % (at the atmospheric air) crp of the blood serum > 10 mg/l ct changes typical of viral lesions (minimal or moderate lesion vol-ume; ct 1-2, no more than 72 hours before screening) patients meeting the requirements of the clinical study protocol; negative pregnancy test (for women with preserved reproductive potential).

inclusion criteria: patients who are able to sign the informed consent form to partic-ipate in the clinical study; patients of both sexes at the age of 18-65 years of age; positive sars-cov-2 rna test result obtained by pcr during the current episode of covid-19 disease; one or more clinical manifestations of ari (acute respiratory infection) or patient complaints: cough (dry or scanty sputum), edema (including during exercise), chest congestion, sore throat, nasal congestion, or mild rhinorrhea, impairment or loss of smell (hyposmia or anosmia), loss of taste (dysgeusia), conjunctivitis, weakness, muscle pain, headache, vomiting, diarrhea, skin manifestations). patients with a moderate course of covid-19, determined on the basis of at least one of the criteria specified in the interim guide-lines of the ministry of health (assessed from the moment of mani-festation of the disease symptoms): body т > 38 °c rr > 22/min spo2 < 95 % (at the atmospheric air) crp of the blood serum > 10 mg/l ct changes typical of viral lesions (minimal or moderate lesion vol-ume; ct 1-2, no more than 72 hours before screening) patients meeting the requirements of the clinical study protocol; negative pregnancy test (for women with preserved reproductive potential).

inclusion criteria: 1. patients who are able to sign the informed consent form to partic-ipate in the clinical study; 2. patients of both sexes at the age of 18-65 years of age; 3. positive sars-cov-2 rna test result obtained by pcr during the current episode of covid-19 disease; 4. one or more clinical manifestations of ari (acute respiratory infection) or patient complaints: cough (dry or scanty sputum), edema (including during exercise), chest congestion, sore throat, nasal congestion, or mild rhinorrhea, impairment or loss of smell (hyposmia or anosmia), loss of taste (dysgeusia), conjunctivitis, weakness, muscle pain, headache, vomiting, diarrhea, skin manifestations). 5. patients with a moderate course of covid-19, determined on the basis of at least one of the criteria specified in the interim guide-lines of the ministry of health (assessed from the moment of mani-festation of the disease symptoms): - body т > 38 °c - rr > 22/min - spo2 < 95 % (at the atmospheric air) - crp of the blood serum > 10 mg/l 6. ct changes typical of viral lesions (minimal or moderate lesion vol-ume; ct 1-2, no more than 72 hours before screening) 7. patients meeting the requirements of the clinical study protocol; 8. negative pregnancy test (for women with preserved reproductive potential).

inclusion criteria: 1. patients who are able to sign the informed consent form to partic-ipate in the clinical study; 2. patients of both sexes at the age of 18-65 years of age; 3. positive sars-cov-2 rna test result obtained by pcr during the current episode of covid-19 disease; 4. one or more clinical manifestations of ari (acute respiratory infection) or patient complaints: cough (dry or scanty sputum), edema (including during exercise), chest congestion, sore throat, nasal congestion, or mild rhinorrhea, impairment or loss of smell (hyposmia or anosmia), loss of taste (dysgeusia), conjunctivitis, weakness, muscle pain, headache, vomiting, diarrhea, skin manifestations). 5. patients with a moderate course of covid-19, determined on the basis of at least one of the criteria specified in the interim guide-lines of the ministry of health (assessed from the moment of mani-festation of the disease symptoms): - body т > 38 °c - rr > 22/min - spo2 < 95 % (at the atmospheric air) - crp of the blood serum > 10 mg/l 6. ct changes typical of viral lesions (minimal or moderate lesion vol-ume; ct 1-2, no more than 72 hours before screening) 7. patients meeting the requirements of the clinical study protocol; 8. negative pregnancy test (for women with preserved reproductive potential).